drugset / Trial / NCT05542303
A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
NaSequentialOpen-labelTreatment
Summary
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody (mAb) targeting human IGF-1R. This clinical trial will examine the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of ZB001 in healthy Chinese subjects.
Timeline
- Start
- 2022-10-16
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZB001 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | ZB001 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | ZB001 | Monoclonal antibody | 20 mg/kg | Intravenous |
Indications
No indication recorded.